Biotech Co.* (Symbol)

Pharma Co. (Symbol/Country)


Disclosed Funding ($M)

Terms/Details (Date)

Boston Life Sciences Inc. (BLSI)

MDS Nordion Inc. (Canada; unit of MDS Inc.; NYSE:MDZ; TSE:MDS)



MDS will supply Altropane for BLSI's regulatory filing seeking marketing approval for the Parkinson's diagnostic agent; the agreement calls for MDS to also manufacture Altropane for the commercial market if and when it is approved (8/00)

Cepheid (CPHD)

Biomedical Group (unit of Takara Shuzo Co. Ltd.; Japan)

Cepheid Smart Cycler system


The Biomedical Group received an exclusive multi-year agreement to distribute and market the Smart Cycler system to life sciences markets in Japan, Taiwan and South Korea (7/00)

CollaGenex Pharmaceuticals Inc. (CGPI)

Showa Yakuhin Kako Co. Ltd. (Japan)

Showa gains rights to market and supply CollaGenex's Periostat exclusively in Japan, with an option to extend its rights to other Southeast Asian countries


Showa will pay milestone fees associated with the development and regulatory approvals of Periostat in Japan, will coordinate the clinical and regulatory development of Periostat required for marketing authorization by Japan, and either purchase Periostat or develop its own Japanese manufacturing capability, in which case Showa will pay a royalty on net sales to CollaGenex (8/00)

CollaGenexPharmaceuticals Inc. (CGPI)

Taro International Ltd. (subsidiary of Taro Pharmaceutical Industries Ltd.; Israel; TARO)

Taro gains rights to market and supply CollaGenex's Periostat in Israel's dental care market


Taro will pay milestone fees associated with regulatory approvals of Periostat and will be purchasing Periostat from CollaGenex via its wholly owned UK subsidiary, CollaGenex International Ltd.; financial terms were not disclosed (8/00)

Cytogen Corp. (CYTO)

Draximage (subsidiary of Draxis Health Inc.; Canada; TSE:DAX; DRAX)

BrachySeed implant, used in treatment of localized cancers, primarily prostate cancer


Draximage will market and distribute Cytogen's BrachySeed implant, receiving both milestone payments and royalties on sales (9/00)

Mylan Pharmaceuticals (subsidiary of Mylan Laboratories; NYSE:MYL)

Genpharm Inc.*

Two undisclosed Genpharm products


Mylan will market two Genpharm products, with Genpharm as the holder of the U.S. registration and Mylan as the exclusive marketer in the U.S; manufacturing will be coordinated through Genpharm (8/00)

Myriad Genetics Inc. (MYGN)

MDS Inc. (Canada; NYSE:MDZ; TSE:MDS)



Myriad expanded its exclusive marketing collaboration with MDS, allowing MDS to market Colaris colon cancer predictive medicine product in Canada; MDS is Myriad's exclusive marketing partner for hereditary breast and ovarian cancer predictive testing in Canada (10/19)

Nymox Pharmaceutical Corp. (NYMX)

Pharmatech Business Services Inc.*

Distribution and marketing agreement for the 7C Gold NTP test for use in Alzheimer's disease


Nymox will provide the new test as an aid to physicians, and Pharmatech will provide its product distribution, billing, reimbursement and collection services in the U.S. (9/00)


# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments